SBC115 & SBC116
Undisclosed
PreclinicalActive
Key Facts
About SapiensBio
SapiensBio is a preclinical-stage biotech utilizing its AI platform, Sapientia, for novel drug discovery, with a focus on idiopathic pulmonary fibrosis. Its lead candidate, SBC101, has received positive FDA Pre-IND feedback and is preparing for Phase 1 trials. The company is actively pursuing licensing deals and investment, positioning itself at a key inflection point as it transitions into clinical development.
View full company profileTherapeutic Areas
Other Undisclosed Drugs
| Drug | Company | Phase |
|---|---|---|
| Preclinical ISAC 1 | Bolt Biotherapeutics | Preclinical |
| Preclinical ISAC 2 | Bolt Biotherapeutics | Preclinical |
| ART12.11 | Artelo Biosciences | Preclinical |
| Novel Vaccines | MSD | Development |
| SLS-009 | Seelos Therapeutics | Discovery |
| Technosphere Platform (New Formulations) | MannKind | Discovery/Preclinical |
| Measovir®-based Prophylactic Vaccine (with Unither) | Oncovita | Research/Pre-clinical |
| Internal sdAb Discovery Program | NanoTag Biotechnologies | Discovery |
| NB-701 | Nerai Biosciences | Discovery |
| Undisclosed Therapeutic Program(s) | Bright Cell | Clinical Trial (Phase unspecified) |
| Biosimilars Pipeline | Intelligent Therapeutics | Pre-clinical/Development |
| Proprietary Therapeutic Pipeline | Excelsior Sciences | Discovery |